Dasatinib Drugs Market Growth Accelerates: Strategic Forecast Predicts $1.95 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Dasatinib Drugs Industry Market Size Be by 2025?
The market for dasatinib drugs has experienced robust growth in recent years, projecting to escalate from $1.45 billion in 2024 to $1.53 billion in 2025. This equates to a compound annual growth rate (CAGR) of 5.8%. Factors contributing to this unprecedented expansion during this historic period include the rising prevalence of chronic myeloid leukemia (CML), the progress made in targeted cancer therapies, the extensive research into tyrosine kinase inhibitors (TKIS), the surge in oncology research investment, and an increase in the number of clinical trials.

What's the Long-Term Growth Forecast for the Dasatinib Drugs Market Size Through 2029?
In the forthcoming years, a robust increase in growth is anticipated for the dasatinib drugs market, rising to "$1.95 billion in 2029 with a compound annual growth rate (CAGR) of 6.3%. This predicted surge during the forecast period is due to factors such as enhanced investments in oncological drug research, an increase in drug-resistant leukemia conditions, the expansion of generic dasatinib drugs, efforts towards reducing chemotherapy side effects, and heightened awareness and early detection of leukemia. Some of the significant trends forecasted for this period include the embrace of personalized medicine, the application of companion diagnostics, the creation of new formulations, progress in combination treatments, and the introduction of biosimilars.

View the full report here:
https://www.thebusinessresearchcompany.com/report/dasatinib-drugs-global-market-report

What Are the Key Growth Drivers Fueling the Dasatinib Drugs Market Expansion?
The rise in chronic myeloid leukemia (CML) cases is anticipated to boost the dasatinib drug market's expansion. This form of cancer, which affects bone marrow and blood, is marked by the abnormal proliferation of white blood cells. Factors such as lifestyle demographics, poor diet, and increasing environmental risks are contributing to a surge in CML prevalence. Dasatinib drugs, which inhibit BCR-ABL (a gene fusion) activity, prove useful in treating CML. This tyrosine kinase protein, generated by the Philadelphia chromosome mutation, stimulates unregulated growth of cancerous white blood cells. For instance, data from the American Cancer Society (ACS), a US-based health organization committed to eradicating cancer, shows an increase in CML cases in the United States - going from 8,860 in 2022 to 8,930 in January 2023. Consequently, the escalating occurrence of chronic myeloid leukemia (CML) is fueling growth in the dasatinib drug market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19023&type=smp

What Long-Term Trends Will Define the Future of the Dasatinib Drugs Market?
Prominent corporations in the dasatinib drugs market are concentrating on the production of generic medications to grow their market presence, offer economical treatment alternatives, and enhance patient accessibility. Generic drugs in the dasatinib sector provide more budget-friendly treatment possibilities, improving patient accessibility, fostering competition, and reducing healthcare expenses. For example, Apotex Corp., a Canadian pharmaceutical firm, in September 2024, introduced the first generic version of Sprycel dasatinib in the United States to treat specific leukemias in adults and children. This cost-effective solution enhances the availability of high-quality treatment choices. This groundbreaking move represents a crucial stride in escalating competition and decreasing prices in the dasatinib market.

How Is the Dasatinib Drugs Market Segmented?
The dasatinib drugs market covered in this report is segmented -

1) By Product Type: Tablets, Oral Suspension, Other Products
2) By Indication: Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Other Indications
3) By End User: Hospitals, Specialty Clinics, Home Healthcare

Subsegments:
1) By Tablets: 20 mg Tablets, 50 mg Tablets, 70 mg Tablets, 80 mg Tablets
2) By Oral Suspension: 20 mg Or 5 mL Oral Suspension, 40 mg Or 5 mL Oral Suspension
3) By Other Products: Injectable Formulations, Combination Therapies, Generic Dasatinib Products

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=19023&type=smp

Which Companies Are Leading the Charge in Dasatinib Drugs Market Innovation?
Major companies operating in the dasatinib drugs market are Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sandoz Group AG, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, MSN Laboratories Pvt. Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Intas Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Mylan N.V., Manus Aktteva Biopharma LLP

Which Regions Are Leading the Global Dasatinib Drugs Market in Revenue?
North America was the largest region in the dasatinib drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dasatinib drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19023

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Reach Out to Us
Speak With Our Expert:Saumya Sahay,
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267,
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com
Follow Us On:LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.